公开(公告)号：EP4431617A1

公开(公告)日：2024-09-18

申请号：EP23162720.9

申请日：2023-03-17

申请人： Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft ,  Charité - Universitätsmedizin Berlin

发明人： de la Rosa, Kathrin ,  Vázquez García, Clara ,  Obermayer-Wasserscheid, Benedikt

IPC分类号： C12Q1/6869 ,  C12Q1/6883

CPC分类号： C12Q1/6869 ,  C12Q1/6886 ,  C12Q2600/15620130101 ,  C12Q2600/11820130101

摘要： The present invention relates to a method for analyzing the DNA break repair machinery of a subject, in particular, for determining at least one deficiency in the DNA break repair machinery, and, on this basis, for predicting the DNA break repair efficiency of the subject. While the analysis is performed in B-cells and comprises analyzing switch-joints of the immunoglobulin heavy chain locus (!GH) of said B-cells, the results can generally be used to predict the risk to develop a cancer, an immunodeficiency such as common variable immunodeficiency (CVID) or a neurodevelopmental disease such as ataxia telangiectasia (AT), for determining the prognosis of a cancer, or for selecting a method of treating a cancer. The invention also relates to a computer program product comprising instructions which, when the program is executed by a computer, cause the computer to carry out specific steps of the analysis, and to a kit comprising said computer program product. The method of the invention is also designated Switch-joint Breakpoint Repertoire Identification (SWIBRID).

公开(公告)号：EP3932402A1

公开(公告)日：2022-01-05

申请号：EP20183093.2

申请日：2020-06-30

申请人： Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

发明人： de la Rosa, Kathrin

IPC分类号： A61K31/341 ,  A61K31/451 ,  A61K31/496 ,  A61K31/54 ,  A61K39/00 ,  A61K45/06 ,  A61P31/14

摘要： The invention relates to an ADAM17 inhibitor for use in the prevention and/or treatment of COVID-19 in a subject.
The invention further relates to a pharmaceutical composition comprising an ADAM17 inhibitor as an active ingredient for use in the prevention and/or treatment of COVID-19 in a subject.
The invention further relates to a kit of parts for use in the prevention and/or treatment of COVID-19 in a subject comprising i) an ADAM17 inhibitor and ii) a vaccine.
The invention further relates to a pharmaceutical composition comprising an ADAM17 inhibitor and an active immunization vaccine.
The invention further relates to a kit of parts comprising i) an ADAM17 inhibitor and ii) an active immunization vaccine.
The invention further relates to a method of preventing and/or treating COVID-19 in a subject, in the need thereof.